CTD Holdings, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. The company’s lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Neimann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. CTD Holdings, Inc. was founded in 1990 and is based in Gainesville, Florida.